Identification of clinically actionable variants from genome sequencing of families with congenital heart disease

Article metrics

Abstract

Purpose

Congenital heart disease (CHD) affects up to 1% of live births. However, a genetic diagnosis is not made in most cases. The purpose of this study was to assess the outcomes of genome sequencing (GS) of a heterogeneous cohort of CHD patients.

Methods

Ninety-seven families with probands born with CHD requiring surgical correction were recruited for genome sequencing. At minimum, a proband–parents trio was sequenced per family. GS data were analyzed via a two-tiered method: application of a high-confidence gene screen (hcCHD), and comprehensive analysis. Identified variants were assessed for pathogenicity using the American College of Medical Genetics and Genomics–Association for Molecular Pathology (ACMG-AMP) guidelines.

Results

Clinically relevant genetic variants in known and emerging CHD genes were identified. The hcCHD screen identified a clinically actionable variant in 22% of families. Subsequent comprehensive analysis identified a clinically actionable variant in an additional 9% of families in genes with recent disease associations. Overall, this two-tiered approach provided a clinically relevant variant for 31% of families.

Conclusions

Interrogating GS data using our two-tiered method allowed identification of variants with high clinical utility in a third of our heterogeneous cohort. However, association of emerging genes with CHD etiology, and development of novel technologies for variant assessment and interpretation, will increase diagnostic yield during future reassessment of our GS data.

Access options

Rent or Buy article

Get time limited or full article access on ReadCube.

from$8.99

All prices are NET prices.

Fig. 1
Fig. 2
Fig. 3

References

  1. 1.

    van der Linde D, Konings EE, Slager MA, et al. Birth prevalence of congenital heart disease worldwide: a systematic review and meta-analysis. J Am Coll Cardiol. 2011;58:2241–2247.

  2. 2.

    Marelli AJ, Ionescu-Ittu R, Mackie AS, Guo L, Dendukuri N, Kaouache M. Lifetime prevalence of congenital heart disease in the general population from 2000 to 2010. Circulation. 2014;130:749–756.

  3. 3.

    Blue GM, Kirk EP, Giannoulatou E, et al. Advances in the genetics of congenital heart disease: a clinician’s guide. J Am Coll Cardiol. 2017;69:859–870.

  4. 4.

    Lionel AC, Costain G, Monfared N, et al. Improved diagnostic yield compared with targeted gene sequencing panels suggests a role for whole-genome sequencing as a first-tier genetic test. Genet Med. 2018;20:435–443.

  5. 5.

    Stavropoulos DJ, Merico D, Jobling R, et al. Whole genome sequencing expands diagnostic utility and improves clinical management in pediatric medicine. NPJ Genom Med. 2016;1:1–9.

  6. 6.

    Richards S, Aziz N, Bale S, et al. Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology. Genet Med. 2015;17:405–424.

  7. 7.

    Szot JO, Cuny H, Blue GM, et al. A screening approach to identify clinically actionable variants causing congenital heart disease in exome data. Circ Genom Precis Med. 2018;11:1–11.

  8. 8.

    Blue GM, Kirk EP, Giannoulatou E, et al. Targeted next-generation sequencing identifies pathogenic variants in familial congenital heart disease. J Am Coll Cardiol. 2014;64:2498–2506.

  9. 9.

    Li H. Exploring single-sample SNP and INDEL calling with whole-genome de novo assembly. Bioinformatics. 2012;28:1838–1844.

  10. 10.

    Rimmer A, Phan H, Mathieson I, et al. Integrating mapping-, assembly- and haplotype-based approaches for calling variants in clinical sequencing applications. Nat Genet. 2014;46:912–918.

  11. 11.

    Wang K, Li M, Hakonarson H. ANNOVAR: functional annotation of genetic variants from high-throughput sequencing data. Nucleic Acids Res. 2010;38:e164.

  12. 12.

    Aken BL, Achuthan P, Akanni W, et al. Ensembl 2017. Nucleic Acids Res. 2017;45:D635–D642.

  13. 13.

    Rausch T, Zichner T, Schlattl A, Stutz AM, Benes V, Korbel JO. DELLY: structural variant discovery by integrated paired-end and split-read analysis. Bioinformatics. 2012;28:i333–i339.

  14. 14.

    Munro JE, Dunwoodie SL, Giannoulatou E. SVPV: a structural variant prediction viewer for paired-end sequencing datasets. Bioinformatics. 2017;33:2032–2033.

  15. 15.

    Kearney HM, Thorland EC, Brown KK, Quintero-Rivera F, South ST, Working Group of the American College of Medical Genetics Laboratory Quality Assurance C. American College of Medical Genetics standards and guidelines for interpretation and reporting of postnatal constitutional copy number variants. Genet Med. 2011;13:680–685.

  16. 16.

    Lin AE, Birch PH, Korf BR, et al. Cardiovascular malformations and other cardiovascular abnormalities in neurofibromatosis 1. Am J Med Genet A. 2000;95:108–117.

  17. 17.

    Stanczak P, Witecka J, Szydlo A, et al. Mutations in mammalian tolloid-like 1 gene detected in adult patients with ASD. Eur J Hum Genet. 2009;17:344–351.

  18. 18.

    Clark TG, Conway SJ, Scott IC, et al. The mammalian Tolloid-like 1 gene, Tll1, is necessary for normal septation and positioning of the heart. Development. 1999;126:2631–2642.

  19. 19.

    Sukalo M, Tilsen F, Kayserili H, et al. DOCK6 mutations are responsible for a distinct autosomal-recessive variant of Adams-Oliver syndrome associated with brain and eye anomalies. Hum Mutat. 2015;36:593–598.

  20. 20.

    Kosaki R, Gebbia M, Kosaki K, et al. Left-right axis malformations associated with mutations in ACVR2B, the gene for human activin receptor type IIB. Am J Med Genet. 1999;82:70–76.

  21. 21.

    Southgate L, Sukalo M, Karountzos ASV, et al. Haploinsufficiency of the NOTCH1 receptor as a cause of Adams-Oliver syndrome with variable cardiac anomalies. Circ Cardiovasc Genet. 2015;8:572–581.

  22. 22.

    Shi H, Enriquez A, Rapadas M, et al. NAD deficiency, congenital malformations, and niacin supplementation. N Engl J Med. 2017;377:544–552.

  23. 23.

    Roosing S, Hofree M, Kim S, et al. Functional genome-wide siRNA screen identifies KIAA0586 as mutated in Joubert syndrome. eLife. 2015;4:e06602.

  24. 24.

    Sanchez-Castro M, Pichon O, Briand A, et al. Disruption of the SEMA3D gene in a patient with congenital heart defects. Hum Mutat. 2015;36:30–33.

  25. 25.

    Degenhardt K, Singh MK, Aghajanian H, et al. Semaphorin 3d signaling defects are associated with anomalous pulmonary venous connections. Nat Med. 2013;19:760–765.

  26. 26.

    Wouters V, Limaye N, Uebelhoer M, et al. Hereditary cutaneomucosal venous malformations are caused by TIE2 mutations with widely variable hyper-phosphorylating effects. Eur J Hum Genet. 2010;18:414–420.

  27. 27.

    Dentici ML, Barresi S, Niceta M, et al. Clinical spectrum of Kabuki-like syndrome caused by HNRNPK haploinsufficiency. Clin Genet. 2018;93:401–407.

  28. 28.

    Koemans TS, Kleefstra T, Chubak MC, et al. Functional convergence of histone methyltransferases EHMT1 and KMT2C involved in intellectual disability and autism spectrum disorder. PLoS Genet. 2017;13:e1006864.

  29. 29.

    Jin SC, Homsy J, Zaidi S, et al. Contribution of rare inherited and de novo variants in 2,871 congenital heart disease probands. Nat Genet. 2017;49:1593–1601.

  30. 30.

    Durst R, Sauls K, Peal DS, et al. Mutations in DCHS1 cause mitral valve prolapse. Nature. 2015;525:109–113.

  31. 31.

    van Bon BW, Balciuniene J, Fruhman G, et al. The phenotype of recurrent 10q22q23 deletions and duplications. Eur J Hum Genet. 2011;19:400–408.

  32. 32.

    Homsy J, Zaidi S, Shen Y, et al. De novo mutations in congenital heart disease with neurodevelopmental and other congenital anomalies. Science. 2015;350:1262–1266.

  33. 33.

    Lewin MB, McBride KL, Pignatelli R, et al. Echocardiographic evaluation of asymptomatic parental and sibling cardiovascular anomalies associated with congenital left ventricular outflow tract lesions. Pediatrics. 2004;114:691–696.

  34. 34.

    Costain G, Jobling R, Walker S, et al. Periodic reanalysis of whole-genome sequencing data enhances the diagnostic advantage over standard clinical genetic testing. Eur J Hum Genet. 2018;26:740–744.

  35. 35.

    Nykamp K, Anderson M, Powers M, et al. Sherloc: a comprehensive refinement of the ACMG-AMP variant classification criteria. Genet Med. 2017;19:1105–1117.

  36. 36.

    Tavtigian SV, Greenblatt MS, Harrison SM, et al. Modeling the ACMG/AMP variant classification guidelines as a Bayesian classification framework. Genet Med 2018.

  37. 37.

    Short PJ, McRae JF, Gallone G, et al. De novo mutations in regulatory elements in neurodevelopmental disorders. Nature. 2018;555:611–616.

  38. 38.

    Liu Y, Liang Y, Cicek AE, et al. A statistical framework for mapping risk genes from de novo mutations in whole-genome-sequencing studies. Am J Hum Genet. 2018;102:1031–1047.

  39. 39.

    Alfares A, Aloraini T, Subaie LA, et al. Whole-genome sequencing offers additional but limited clinical utility compared with reanalysis of whole-exome sequencing. Genet Med. 2018:1–6.

  40. 40.

    Christensen KD, Vassy JL, Phillips KA, et al. Short-term costs of integrating whole-genome sequencing into primary care and cardiology settings: a pilot randomized trial. Genet Med. 2018:1–10.

Download references

Acknowledgements

This work was supported by the National Health and Medical Research Council (NHMRC) (fellowships ID1135886, ID1042002 to S.L.D., ID573732 to R.P.H, and ID1105271 to J.W.K.H. and program grant ID1074386 to R.P.H., R.M.G., S.L.D.); Australian National Heart Foundation (fellowship ID100848 to J.W.K.H. and ID101204 to E.G.); Australian Postgraduate Award (UNSW) (J.O.S., E.I.); Office of Health and Medical Research NSW Government to S.L.D., R.P.H, R.M.G; Chain Reaction (The Ultimate Corporate Bike Challenge) to S.L.D.; Channel 7 Telethon to S.L.D., R.M.G.; and The Key Foundation to S.L.D. The authors would like to thank all families who took part in the study. The authors also thank Elizabeth Anderson for assistance with analysis.

Author information

Correspondence to Sally L. Dunwoodie BSc, PhD.

Ethics declarations

Disclosure

The authors declare no conflicts of interest.

Electronic supplementary material

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Alankarage, D., Ip, E., Szot, J.O. et al. Identification of clinically actionable variants from genome sequencing of families with congenital heart disease. Genet Med 21, 1111–1120 (2019) doi:10.1038/s41436-018-0296-x

Download citation

Keywords

  • congenital heart disease
  • genetic diagnosis
  • genome sequencing
  • clinical utility
  • ACMG

Further reading